



Proventa International's 12th Annual
MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2025

Thursday, 8th May 2025

Le Méridien Boston Cambridge

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Visit our
website
for future
← events

Featuring Industry Leaders and Decision Makers:



Govinda Bhisetti
Vice President and
Head of Computational
Chemistry
Cellarity



Markus Haerberlein
Executive Vice President,
Discovery Science
**Parabiolis
Medicines**



Hua Xu
Director, Head of
Chemical Biology and
Proteomics
AstraZeneca



Lee Fader
Vice President
**Congruence
Therapeutics**



Aimee Usera
Senior Vice President
Drug Discovery
**Delphia
Therapeutics**



Jennifer Petter
Founder and Chief
Scientific Officer,
**Arrakis
Therapeutics**



Rich Heidebrecht
Vice President of
Research and
Development
Glycologix



24
ROUNDTABLE
DISCUSSIONS



6
TRACKS



2
KEYNOTE
PRESENTATIONS



1
PANEL
DISCUSSION



1
LOCATION



What Makes
Our Strategy
Meetings
So Unique?

Proud to Partner with:



Proventa International's Strategy Meetings are a completely unique experience.

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2025

Thursday, 8th May 2025

Le Méridien Boston Cambridge

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.



Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.



Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format



ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.



INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.




STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Medicinal Chemistry

- ✓ Medicinal Chemistry
- ✓ R&D
- ✓ Drug Discovery
- ✓ Computational Chemistry
- ✓ Cheminformatics
- ✓ CMC
- ✓ External Innovation
- ✓ Pre-Clinical
- ✓ Artificial Intelligence

Meet Investors

- ✓ Venture Capital
- ✓ Private Equity
- ✓ Large Pharma/Biotech
- ✓ Corporate Venture Capital
- ✓ Institutional
- ✓ High Net Worth
- ✓ Family Office/Private Wealth
- ✓ Government Organisation/
- ✓ Sovereign Wealth Fund
- ✓ Angel

Facilitator Faculty

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2025

📅 Thursday, 8th May 2025

📍 Le Méridien Boston Cambridge



Nicolas Triballeau, Ph.D
Director of Small Molecule Drug Discovery
Revvity Signals



Samantha Jeschonek Ph.D
Sr. Product Manager Data Analytics
Revvity Signals



David Gosalvez
Chief Strategy Officer
Revvity Signals



Maneesh Pingle
EVP & Head of Discovery Services
SAI Life Sciences



Kelly Barrett
Business Development Professional
SAI Life Sciences



Dr. Tao Guo
SVP and Head
WuXi AppTec



Aimee Usera
Senior Vice President Drug Discovery
Delphia Therapeutics



Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics



David Sherris
Chief Executive Officer
Attivare Therapeutics



Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University



Claire Elizabeth Smith
Partner
SpringTide Ventures



Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity



Hajnalka Hartl
Head of Chemistry
Orogen Therapeutics



Huseyin Mehmet
Executive Director
University of Massachusetts Medical School



Hua Xu
Director, Head of Chemical Biology and Proteomics
AstraZeneca



Jennifer Petter
Founder and Chief Scientific Officer
Arrakis Therapeutics



Lee Fader
Vice President
Congruence Therapeutics



Lu Gong
Head of Bioinformatics and AI
Simcere Pharma



Markus Haeblerlein
Executive Vice President, Discovery Science
Parablis Medicines



Matthew Lucas
Former VP Chemistry
Third Harmonic Bio



Michal Preminger
Former Head of Innovation, East North America
Johnson & Johnson Innovation



Rich Heidebrecht
Vice President of Research and Development
Glycologix



Rocky Goldsmith
Chief Innovation Scientist / Co-Founder
Congruence Therapeutics



Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics



Stefan Gross
Senior Director and Head of Biochemistry
Servier Pharmaceuticals



Stephanie Oestreich
Managing Director
Myeloma Investment Fund

2025 Sponsors

MEDICINAL CHEMISTRY STRATEGY MEETING EAST COAST USA 2025

📅 Thursday, 8th May 2025

📍 Le Méridien Boston Cambridge

LEAD SPONSOR



Revvity Signals Software provides an extensive range of scientific solutions, empowering researchers and pharmaceutical pioneers worldwide. Our cutting-edge technology simplifies processes, speeds up experiments, and prioritizes promising compounds, redefining drug discovery. The Signals Research Suite, our flagship solution, streamlines R&D workflows with data capture, collaboration, data processing, and data-driven analytics. It includes i Signals Notebook, the only cloud-native electronic lab notebook with ChemDraw®, Spotfire® powered advanced analytics, as well as next-gen data management. In addition, we have recently introduced Signals Synergy which is designed to substantially enhance collaboration, project management, and data exchange between sponsors and CROs

THOUGHT LEADER



Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India's fastest growing CDMOs, the company is investing over US \$ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

CO-HOST SPONSOR



WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.
<http://www.wuxiapptec.com>

PARTNERING SPONSORS



RG Discovery provides premium services within two major areas: Drug Discovery and Analytical Services & Advanced Chemistry. Our expertise and focus are small molecules, macrocycles and peptides. We are based in the vibrant Medicon Valley region close to Copenhagen. Drug Discovery highlights

- Expertise in medicinal chemistry, computational science, in vitro biology, ADME, and fragment-based drug discovery
- Design and synthesis of small molecules, peptides, macrocycles and drug conjugates
- All R&D functions and teams under one roof enabling fast design-make-test cycles
- Experience across target classes and indications
- Track record of project deliveries from hit finding to clinical candidates



Apex Molecular are a leading UK based CRO providing expert medicinal and synthetic chemistry services to the Life Science Industry. Operating in the preclinical space, our high-quality team can accelerate your drug discovery projects to the next stage through our exemplary communication and diligence. We hold a full controlled substance licence and have a dedicated High Potency suite, allowing us to operate across several chemical spaces and modalities, including but not limited to as ADCs, CNS and psychedelics, PROTACs and Glues.



Founded in 1996 and headquartered in Irvine, California, **BioDuro-Sundia** is a leading US-based CRDMO. With 2,000+ scientists, we have 7 sites across the US and China. We provide fully integrated services spanning drug discovery to commercial manufacturing, covering medicinal chemistry, biology, DMPK, drug substance, and drug product development. Our expertise includes various modalities such as small molecules, peptides, oligonucleotides, and antibody-drug conjugates (ADCs). The drug discovery team, with 1,100+ chemists, serves 330+ global clients annually, offering accelerated project timelines with <5 days per step and a 99%+ on-time delivery record.



Sapio Sciences' mission is to improve life in the lab - because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and data solutions. Sapio serves some of the largest global and niche brands, including biopharma, CRO's and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Our customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.



Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in silico, optimized to meet all key success criteria of a discovery project. Available as SaaS software and through strategic collaborations with pharmaceutical companies, Iktos combines AI-driven molecular design with robotic synthesis and biological testing, accelerating drug discovery. With over 60 successful projects to date, Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. Iktos completed a €15.5M Series A financing round, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. For more information, visit iktos.ai.



Inductive Bio's ADMET Machine Learning (ML) platform accelerates compound optimization, helping medicinal chemists identify the best development candidates. With real-time ADMET liability evaluation, Inductive's platform guides critical design and prioritization decisions toward the most promising ideas. Trained on thousands of data points from proprietary consortium programs, in-house generation, and curated public sources, Inductive's ADMET foundation models empower partners to design high-quality compounds and reduce time to key milestones.



In the high-stakes field of drug discovery, where R&D costs are high and failure rates significant, companies are turning to AI-driven solutions. With precision and efficiency being paramount, **DrugBank** has emerged as the leading data partner. DrugBank is designed to enhance drug research through an evidence-based approach. DrugBank ensures access to accurate and current drug data bridging valuable information across numerous sources, establishing meaningful connections within the data. The time savings provided by DrugBank in early phases of drug development are crucial. DrugBank is an essential partner dedicated to rapid progression of your projects from discovery through to market.



Jubilant Biosys Ltd. Is a part of Jubilant Pharmova group of companies with R&D centres in India and business offices in Asia, North America, UK and EU. Jubilant Biosys provides comprehensive drug discovery, contract research, development and manufacturing services. Our drug discovery services range from target validation to candidate selection, and CDMO services offer manufacturing support from clinical to commercial stage. We offer stand-alone services across entire continuum of drug discovery, including computational, medicinal, synthetic & analytical chemistry, structural biology, in-vivo & in-vitro biology, DMPK/ADME & toxicology. Our scale up & manufacturing facility in India with 900+ MTs reactor capacity is accredited by U.S. FDA, PMDA, and EMA. Tech. transfer from lab scale synthesis to manufacturing is supported by our on-site R&D, QC, QA, EHS, PM and engineering experts. This is indeed the reason why Jubilant Biosys is a partner of choice for pharma & biotech companies across the globe.

EXHIBITORS





Agenda at a Glance

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2025

📅 Thursday, 8th May 2025 📍 Le Méridien Boston Cambridge

TRACK 1


































TRACK 2

TRACK 3

TRACK 4

TRACK 5

TRACK 6

TIME	AI/ML	DESIGN, SYNTHESIS, & EMERGING MODALITIES	CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION AND UNDRUGGABLES	TARGET IDENTIFICATION/LEAD OPTIMIZATION	STRATEGIC PARTNERSHIPS IN DRUG DISCOVERY	INTEGRATED DRUG DISCOVERY
EST						
BOARDROOM ►	Jerome C. Hunsaker A	Jerome C. Hunsaker B	Jerome C. Hunsaker C	Edward Pennell Brooks	Margaret L.A. Macvicar	Lan Jen Chu
08:00 - 08:30	BREAKFAST & REGISTRATION					
08:30 - 09:00	OPENING KEYNOTE PRESENTATION: A Structure-based Approach to Drugging RNA with Small Molecules  Jennifer Petter, Founder and Chief Scientific Officer, Arrakis Therapeutics					
09:00 - 10:00 PHARMA/ BIOTECH	Generative Chemistry in Action: Applications, Challenges, and Breakthroughs  Govinda Bhisetti, Vice President and Head of Computational Chemistry, Cellarity	Unlocking the Chemical Universe: The Power of DNA-Encoded Libraries in Drug Discovery  Hajnalka Hartl, Head of Chemistry, Orogen Therapeutics	Leveraging Chemical Biology and Proteomics Technologies to Advance Therapeutics for Intractable Targets  Hua Xu, Director, Head of Chemical Biology and Proteomics, AstraZeneca	Fragment Based Drug Discovery  Stefan Gross, Senior Director and Head of Biochemistry, Servier Pharmaceuticals	Beyond Algorithms: Forging Strategic Alliances to Power the AI Revolution in Drug Discovery  Diane Joseph-McCarthy, Executive Director, Bioengineering Technology & Entrepreneurship Center, Boston University	From Hit to Lead: Accelerating Drug Discovery Through Cutting-Edge Chemistry and Innovative Screening Strategies  Shankar Venkatraman, Executive Director, Chemistry, IFM Therapeutics
10:00 - 10:05	REFRESHMENT BREAK					
10:05 - 10:25	NETWORKING / 1-1 MEETINGS					
10:25 - 10:45	NETWORKING / 1-1 MEETINGS					
10:45 - 11:05	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10 SOLUTION		Navigating Multi-Dimensional Complexity in Emerging Modalities: How Integrated Platforms Are Transforming PROTACs and ADC Development  Nicolas Triballeau, Ph.D, Director of Small Molecule Drug Discovery, Revvity Signals REVVITY SIGNALS 	Targeted Protein Degradation  Dr. Tao Guo, SVP and Head, WuXi AppTec WUXI APPTEC 	Lead optimisation of proximity inducing modalities  Maneesh Pingle, EVP & Head of Discovery Services, SAI Life Sciences SAI LIFE SCIENCES 	Unlocking the Power of Partnership in Drug Discovery  Kelly Barrett, Business Development Professional, SAI Life Sciences SAI LIFE SCIENCES 	The Data Integration Crisis in Drug Discovery: Why Scientists Spend 60% of Their Time on Data Wrangling Instead of Breakthrough Science  Samantha Jeschonek, Ph.D, Sr. Product Manger Data Analytics, Revvity Signals REVVITY SIGNALS 
12:15 - 13:15 PHARMA/ BIOTECH	Explainable AI (XAI) and ML/AL as assistive intelligence to support rational lead optimization of small molecules  Rocky Goldsmith, Chief Innovation Scientist / Co-Founder, Congruence Therapeutics	Rational Design Meets Fragmentation: Bridging Structural Biology and Fragment-Based Discovery for Novel Therapeutic Modalities  Shankar Venkatraman, Executive Director, IFM Therapeutics	From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins  Benoit Moreau, Head of Medicinal Chemistry, Remix Therapeutics	Drugging Protein:Protein Interactions: Best practices in hit identification and lead optimization of undruggable complexes  Aimee Usera, Senior Vice President Drug Discovery, Delphia Therapeutics	Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery  Huseyin Mehmet, Executive Director, University of Massachusetts Medical School	
13:15 - 14:00	NETWORKING LUNCH					
14:00 - 14:20	NETWORKING / 1-1 MEETINGS					
14:20 - 14:40	NETWORKING / 1-1 MEETINGS					
14:40 - 15:10	AFTERNOON KEYNOTE PRESENTATION: Augmented Discovery: How Revvity Signals' AI/ML Amplifies Scientific Discovery  David Gosalvez, Chief Strategy Officer, Revvity Signals revvity signals					
15:10 - 16:10 PHARMA/ BIOTECH	Fast-Tracking Innovation: Leveraging AI/ML to Accelerate Drug Discovery  Markus Haerberlein, Executive Vice President, Discovery Science, Parabillis Medicines	Computational & AI-Driven TAA Discovery for Bispecific and Small Molecule ADC Development  Lu Gong, Head of Bioinformatics and AI, Sincere Pharma	Induced Proximity Therapeutics: Drugging Disease Drivers Through Engineered Protein Protein Interaction Enhancers  Matthew Lucas, Former VP Chemistry,, Third Harmonic Bio	The Impact of AI and Large Language Models Across the Drug Discovery Pipeline  Lee Fader, Vice President, Congruence Therapeutics	The Role of Venture Partnerships in Drug Discovery  Rich Heidebrecht, Vice President of Research and Development, Glycologix	Rewriting the Rules of Therapeutics: The Expanding Frontier of RNA Drug Discovery  Jennifer Petter, Founder and Chief Scientific Officer, Arrakis Therapeutics
16:10 - 16:30	AFTERNOON REFRESHMENT BREAK					
16:30 - 17:00	PANEL DISCUSSION: Biotech Investment Today: Navigating the Shifting Landscape  CHAIRPERSON: Michal Preminger, Former Head of Innovation, East North America, Johnson & Johnson Innovation  PANELIST: Stephanie Oestreich, Managing Director, Myeloma Investment Fund  PANELIST: David Sherris, Chief Executive Officer, Attivare Therapeutics  PANELIST: Claire Elizabeth Smith, Partner, SpringTide Ventures					
17:00 - 18:00	DRINKS & CANAPES RECEPTION					



VENTURE CAPITAL & PRIVATE EQUITY STRATEGY MEETING EAST COAST USA 2025

📅 **Wed/Thurs, 7-8th May 2025** 📍 **Le Méridien Boston Cambridge**

Investment Challenges and Opportunities in Emerging Biotech Markets



Scan to Register

Featuring Industry Leaders and Decision Makers:



Claire Elizabeth Smith
Partner
SpringTide Ventures



Robert Gabriel
Board Member,
Managing Partner
Ashur Capital



David Sherris
CEO
Attivare Therapeutics



What Makes
Our Strategy
Meetings
So Unique?

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 614 0377







✉ info@proventainternational.com

🌐 Proventa International

🐦 @proventaintl

📘 @proventainternational



	DAY 1	DAY 2
TIME	INVESTMENT IN CLINICAL TRIALS & MANUFACTURING	INVESTMENT IN DRUG DISCOVERY & BIOTECH
EST		
ROOM	Robert R Taylor	Robert R Taylor
08:00 - 08:30	REGISTRATION AND WELCOME	
08:30 - 09:00	OPENING KEYNOTE PRESENTATION: Future Outlook: Investment Opportunities in Emerging Markets for Clinical Trials & Pharmaceutical Manufacturing	OPENING KEYNOTE PRESENTATION: Scaling Biotech Ventures: Challenges and Opportunities for Investors in Drug Discovery Startups
09:00 - 10:00	Balancing Cost-Effectiveness with Data Reliability in Decentralized Models	What Are the Emerging Trends in Venture Capital for Drug Discovery and Biotech Startups?  David Sherris, CEO, Attivare Therapeutics
10:00 - 10:05	REFRESHMENT BREAK	
10:05 - 11:05	NETWORKING / 1-1 MEETINGS	
11:10 - 12:10 SOLUTION	Can the Boom and Bust Cycle of Biotech Investing be Changed?  Doug Zingale, Managing Partner, Blue Goose Capital	2025 Investment Trends: Transforming Drug Discovery Ventures
12:15 - 1:15 Pharma/ Biotech	Exploring the Key Strategies for Improving the Cost-Efficiency of Clinical Trials and Increasing ROI for Investors?  Robert Gabriel, Board Member, Managing Partner, Ashur Capital	Scaling Biotech Ventures: Challenges and Opportunities for Investors in Life Science Startup  Tomasz H. Zastawny, PhD, DSc, Strategic Advisor, Auxilium Pharma
13:15 - 14:00	REFRESHMENT BREAK	
14:00 - 14:40	NETWORKING / 1-1 MEETINGS	
15:10 - 16:10 Pharma/ Biotech	Global Expansion of Clinical Trials: Opportunities and Challenges (Topic TBC)  Dana Callow, Founder & Managing Partner, Boston Millennia Partners	Investment Challenges and Opportunities in Emerging Biotech Markets  Claire Elizabeth Smith, Partner, SpringTide Ventures
16:10 - 16:30	AFTERNOON REFRESHMENT BREAK	
16:30 - 17:00	PANEL DISCUSSION: What Are the Key Success Factors for a Timely and Successful Exit Strategy for Investors?	PANEL DISCUSSION: Venture Strategies for Biotech Startups: Building Scalable Innovations in Drug Discovery
17:00 - 18:00	DRINKS & CANAPES RECEPTION	

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2025

📅 Wednesday, 7th May 2025 📍 Le Méridien Boston Cambridge



🕒 08:30 - 09:00 ET

OPENING KEYNOTE PRESENTATION

A Structure-based Approach to Drugging RNA with Small Molecules



Jennifer Petter

Founder and Chief Scientific Officer
Arrakis Therapeutics

ABOUT THE SPEAKER

Dr. Jennifer Petter is the Founder and Chief Scientific Officer of Arrakis Therapeutics. Previously she was Vice President of Chemistry at Celgene, Vice President of Drug Discovery at Avila Therapeutics, Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen, Section Head in Oncology Chemistry at Sandoz/Novartis, and Assistant Professor of Chemistry at the University of Pittsburgh. Dr. Petter graduated from Dartmouth College with an AB in chemistry, earned her PhD in organic chemistry at Duke University with Ned Porter, and was a post-doctoral fellow in Ron Breslow's group at Columbia University. She has ushered more than a dozen compounds into the clinic for the treatment of cancer, cardiovascular disease, autoimmune disorders, and sepsis.

🕒 14:40 - 15:10 ET

AFTERNOON KEYNOTE PRESENTATION

Augmented Discovery: How Revvity Signals' AI/ML Amplifies Scientific Discovery



David Gosalvez

Chief Strategy Officer
Revvity Signals

ABOUT THE SPEAKER

With two decades of experience in scientific software, **David Gosalvez** brings a rare combination of technical and domain expertise with broad knowledge across scientific use cases. He is a passionate advocate for improving the efficiency and quality of science via innovative software solutions.

🕒 16:30 - 17:00 EST

PANEL DISCUSSION

Biotech Investment Today: Navigating the Shifting Landscape



CHAIRPERSON

Michal Preminger

Former Head of Innovation, East North America
Johnson & Johnson Innovation



PANELIST

Stephanie Oestreich

Managing Director
Myeloma Investment Fund



PANELIST

David Sherris

Chief Executive Officer
Attivare Therapeutics



PANELIST

Claire Elizabeth Smith

Partner
SpringTide Ventures

ABOUT THE SPEAKER

Michal Preminger Panel Chairperson Bio: Until recently, Michal served as Regional Head of Johnson & Johnson Innovation, East North America. In this role, she led the J&J team in sourcing, evaluating, and executing partnerships and investment deals with the most promising early-stage healthcare innovations in the region, with the goal of advancing them into J&J's product pipelines to benefit patients. Previously, Michal held senior leadership roles at Harvard University, overseeing technology development and strategic partnerships at Harvard Medical School. There, she initiated, negotiated, and managed numerous high-impact industry licenses and alliances, helped launch successful startups, and contributed to a cultural shift toward scientific entrepreneurship among faculty and trainees. Earlier in her career, Michal held executive roles in the biotech and tech industries, including at Compugen Ltd (NASDAQ: CGEN). During her current sabbatical, Michal remains active in the innovation ecosystem, among other by serving on the Board of Directors of MassBio and the Kendall Square Association (KSA). Michal holds MSc and PhD degrees from the Weizmann Institute of Science and an MBA from INSEAD.

Despite the reinvigorated R&D engine and reinstated productivity, challenges and opportunities remain unanswered such as optimized druggability, pharmacokinetics and safety, enhanced bioavailability, DNA-Encoded Library, Small and Large Molecules Enhancement, Covalent Fragment Libraries, and more. This track aims to tackle these current barriers, formulate an outlook strategy and explore the emerging modality space.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Unlocking the Chemical Universe: The Power of DNA-Encoded Libraries in Drug Discovery

- Pros and cons of DELs
- Importance of library quality
- Does your target matter?



Hajnalka Hartl
Head of Chemistry
Orogen Therapeutics

ABOUT THE SPEAKER

Hajnalka E. Hartl is Head of Chemistry at Orogen Therapeutics and is a seasoned synthetic and medicinal chemist, bringing over 20 years of experience in small molecule design and synthesis, and expertise in DNA Encoded Library (DEL) technology. Previously she led a small team of chemists at X-Chem, Inc. working on DEL design, development and synthesis. Before that she held a medicinal chemistry position at AstraZeneca, where she worked on multiple anti-infective projects targeting penicillin binding protein PBP3, bacterial NAD⁺-dependent DNA ligase, as well as bacterial DNA gyrase, contributing to the delivery of multiple drug candidates.

10:00 - 11:05 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 EST SOLUTION FOCUS ROUNDTABLE 2

Navigating Multi-Dimensional Complexity in Emerging Modalities: How Integrated Platforms Are Transforming PROTACs and ADC Development



Nicolas Triballeau, Ph.D
Director of Small Molecule Drug Discovery
Revvity Signals

revvity
signals

ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 EST ROUNDTABLE 3

Rational Design Meets Fragmentation: Bridging Structural Biology and Fragment-Based Discovery for Novel Therapeutic Modalities



Shankar Venkatraman
Executive Director
IFM Therapeutics

ABOUT THE SPEAKER

Over his 20+ year industrial career **Shankar Venkatraman** has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology and safety to enter clinical trials with these novel entities. Before joining IFM Therapeutics, LLC, Shankar was a Director of Chemistry at Vitae Pharmaceuticals. There he led number of programs including Menin-MLL, resulting in Revumenib (SNDX-5613), currently undergoing multiple clinical trials for ALL/AML with an anticipated NDA filing by June of 2024. Prior to Vitae, he was a Senior Research Fellow at Merck, where he worked on number of modalities including HIV, neuropathic pain and schizophrenia, and delivered number of clinical candidates. Before joining Merck, Shankar began his medicinal chemistry career at Axyx Pharmaceuticals, and worked on cathepsin K, with efforts leading to the identification of Odanacatib a phase 3 candidate. Shankar obtained his Ph.D. in synthetic organic chemistry from University of Minnesota and B.S. in chemistry from University of Bombay. He is co-author/inventor on more than 60 papers and patents.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

Computational & AI-Driven TAA Discovery for Bispecific and Small Molecule ADC Development



Lu Gong
Head of Bioinformatics and AI
Sincere Pharma

ABOUT THE SPEAKER

A seasoned R&D leader with over a decade of experience in bioinformatics, data science, and immuno-oncology, I currently head Bioinformatics & AI at Sincere Boston Innovation Center. My expertise lies in developing AI-driven platforms for target discovery, including a successful suite for ADC target identification that has advanced three projects to the PCC stage. I'm proficient in functional genomics, CRISPR screening, and machine learning, and have developed AI tools for literature analysis and knowledge management. I bridge wet lab and bioinformatics, with a strong background in molecular biology and NGS. I'm passionate about leveraging cutting-edge technologies to accelerate drug discovery.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
See Page 6

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION



Chemical Biology, Targeted Protein Degradation and Undruggables

This track tackles pressing topics that interrogate and discern biological function by exploring small and large molecule modulation, undruggable targets, Target Protein Degradation, Deep Learning, And Molecular Simulations, and more, to understand probe development better and uncover novel and therapeutically relevant targets.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Leveraging Chemical Biology and Proteomics Technologies to Advance Therapeutics for Intractable Targets

- Ligandability / tractability assessment of challenging targets
- Covalent inhibitors - beyond Cysteine targeting
- Molecular glue discovery for intractables
- Proteomics-based screen for hit discovery



Hua Xu
Director, Head of Chemical Biology and Proteomics
AstraZeneca

ABOUT THE SPEAKER

Hua Xu received his PhD in Chemistry from Stony Brook University. He joined the chemical biology group at Pfizer in 2013, and later received ACS Young Investigator Award in 2016. While at Pfizer, Hua contributed to many drug discovery projects in several therapy areas, including the JAK3/TEC program that led to the approval of ritlecitinib. Hua moved to AstraZeneca in 2021 and currently leads Chemical Biology and Proteomics group that leverages chemical tools and proteomics technologies to enable target discovery and supports projects across therapy areas.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Targeted Protein Degradation



Dr. Tao Guo
SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management
WuXi AppTec



ABOUT THE SPEAKER

Dr. Tao Guo is SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management, WuXi AppTec. He has over 30 years of experience in drug discovery. He was trained as an organic chemist with PhD from Columbia University and PostDoc from UC Berkeley. He is the recipient of 43 issued US patents and an inventor of 10 clinical candidate compounds with 1 approved by FDA.

12:15 - 13:15 ET ROUNDTABLE 3

From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins



Benoit Moreau
Head of Medicinal Chemistry
Remix Pharmaceuticals

ABOUT THE SPEAKER

Benoit Moreau is the head of medicinal chemistry at Remix Therapeutics, a biotech focused on controlling gene and protein expression through modulation of RNA processing. He has over 15 years of experience in drug discovery, building and leading teams in medicinal chemistry at Boehringer Ingelheim, Tarveda and Syros. He contributed to the discovery of several clinical candidates on projects across virology, oncology and rare genetic diseases. He received his PhD in synthetic chemistry from Université de Montréal and completed postdoctoral studies at Harvard University.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

Fresh Life Science Insights

Articles Daily Interviews White Papers

Pharma FEATURES

15:10 - 16:10 ET ROUNDTABLE 4

Induced Proximity Therapeutics: Drugging Disease Drivers Through Engineered Protein Protein Interaction Enhancers

To explore the emerging field of induced proximity therapeutics, with a focus on strategies that enhance—rather than disrupt—protein-protein interactions (PPIs). Panelists will discuss mechanistic foundations, design principles, successful applications, and translational challenges.

- How do we define induced proximity when the therapeutic goal is to stabilize or enhance protein-protein interactions?
- What kinds of molecules or platforms are best suited to promote beneficial PPIs?
- Which disease areas or target classes are particularly amenable to this approach?
- How do we move from molecular insight to clinical candidate?
- Where is the field headed and what gaps remain?



Matthew Lucas
Former VP Chemistry
Third Harmonic Bio

ABOUT THE SPEAKER

Matt Lucas, with more than 20 years of drug discovery experience, most recently held the role of VP Chemistry at Third Harmonic Bio, a biopharmaceutical company focused on dermal, respiratory, and gastrointestinal inflammatory diseases. Other roles have included serving as Chief Science Officer at Gandeeva Therapeutics, and SVP Drug Discovery at Black Diamond Therapeutics where led and contributed to the teams that developed CNS-penetrant EGFR mutant inhibitor BDTX-1535 (currently in Phase 2) for the treatment of glioblastoma and NSCLC, and the RAF inhibitor BDTX-4933, recently licensed by Servier. Matt has also served in leadership roles at Yumanity Therapeutics, Cubist Pharmaceuticals and at Roche Pharmaceuticals, leading multiple projects across therapeutic areas including oncology, immunology, anti-infectives and neuroscience.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
See Page 6

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION

The process of discerning the properties associated with each hit compound is multi-dimensional and impossibly challenging giving rise to the process of eliminating weekly active compounds - Hit to Lead. This track will investigate the steps between target validation to lead optimization, Structure-Based Drug Design Lead, High Throughput Screening, Accelerating Hit-To-Lead Optimization and Progress of Compounds for Lead Optimization, and more.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Fragment Based Drug Discovery

- What makes for a good fragment screening library?
- What is the best hit-finding technology for fragment screening? What are the pros and cons of each option?
- Is a co-crystal structure absolutely required for fragment progression?
- After an initial fragment hit has been identified what Medchem strategies have been employed to progress hits?
- How best to exploit ultra-large virtual or enumerated libraries like Enamines REAL to rapidly progress fragment hits?



Stefan Gross
Senior Director and Head of Biochemistry
Servier Pharmaceuticals

ABOUT THE SPEAKER

Stefan Gross, Ph.D. is Senior Director / Head of Biochemistry at Servier Pharmaceuticals, where his teams located in Boston, Paris, and Shanghai encompass the domains of mechanistic enzymology, structural biology, high-throughput screening, and proteomics. He drives research efforts across the value chain from target identification through post-approval translational product support. Prior to joining Servier in 2021, he spent 19 years as a launch team member in 4 startup ventures, serving as biochemistry lead to 7 clinical candidates and the approved drugs TIBSOVO, IDHIFA, VORANIGO, and PYRUKYND. Stefan is also Professor of Drug Discovery at Tufts University, teaching to excellence across the biomedical career spectrum.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Lead optimisation of proximity inducing modalities

- Improving efficiency during lead optimisation (e.g. D2B, D2DMPK approaches)
- Modelling desirable properties (e.g. Comp Chem, DMPK)
- In-vitro / In-vivo assessment
- What does the future hold?



Maneesh Pingle
EVP & Head of Discovery Services
Sai Life Sciences



ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Drugging Protein:Protein Interactions: Best practices in hit identification and lead optimization of undruggable complexes

- Tackling unique challenges posed by PPIs compared to classic drug targets. How do we address undefined structures, perceived shallow and broad flat pockets, and undruggable interfaces?
- Best practices in screening platforms and identification of functional binders for PPIs.
- Exploration of new trends and technologies for PPI drug discovery including covalent approaches to map PPIs, fragment-based drug discovery, innovative high-throughput screening assays, and AI-empowered virtual screening.



Aimee Usura
Senior Vice President Drug Discovery
Delphia Therapeutics

ABOUT THE SPEAKER

Aimee Usura is a synthetic organic chemist who obtained her PhD from Johns Hopkins University under Professor Gary Posner, and her post doc at MIT working with Professor Sarah O'Connor. Aimee began her career at Novartis Institute for Biomedical Research (NIBR) where she invented new protein chemistry and half-life extension methods, as well as discovered chemical biologic therapeutic clinical candidates. Aimee gained experience across disease areas and modalities, more recently leading the global NIBR Targeted Protein Degradation Initiative. Aimee is currently vice president of chemistry at Odyssey therapeutics where she is focusing on enabling sciences to accelerate the project portfolio.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

The Impact of AI and Large Language Models Across the Drug Discovery Pipeline

- Comparative insights on AI/LLM applications in compound design (Hit-to-Lead, Lead Optimization) vs. target ID/validation and literature mining
- Real-world case studies illustrating successes, bottlenecks, and current limitations
- A critical look at where the hype meets reality—and where innovation is still needed



Lee Fader
Vice President
Congruence Therapeutics

ABOUT THE SPEAKER

With over 20 years of experience in the pharmaceutical industry, **Lee** now holds the role of Vice President of Chemistry at Congruence Therapeutics. Here, he leads small molecule drug discovery effort from the intersection of medicinal chemistry, computational chemistry, and artificial intelligence to discover new medicines for patients suffering from rare diseases.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION See Page 6

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Beyond Algorithms: Forging Strategic Alliances to Power the AI Revolution in Drug Discovery



Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

ABOUT THE SPEAKER

Diane Joseph-McCarthy is the Executive Director of the Bioengineering Technology & Entrepreneurship Center and Professor of the Practice in Biomedical Engineering at Boston University. Prior to that, she was a senior life science executive with over 20 years of drug discovery, development, and leadership experience. She was SVP of Discovery & Early Development at EnBiotix, a bioengineering company focused on respiratory and rare disease. She was an Associate Director at AstraZeneca, where she led a global team and task forces to transform Infection's early portfolio. At Wyeth, she held positions of increasing responsibility. Diane received her PhD from MIT and was a postdoctoral fellow at Harvard University/Harvard Medical School.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Unlocking the Power of Partnership in Drug Discovery

- What defines Strategic vs. Transactional relationships
- Key attributes and criteria for evaluating potential partners.
- Foundations of successful collaboration
- Strategies for maintaining alignment throughout the partnership lifecycle.
- Measuring partnership success



Kelly Barrett

Business Development Professional
SAI Life Sciences



ABOUT THE SPEAKER

Kelly Barrett is a Business Development professional at Sai Life Sciences, where she has spent the past 2+ years supporting strategic partnerships in drug discovery with clients across the biotech, pharmaceutical, and academic sectors. Prior to this role, she spent over 14 years at MilliporeSigma in a range of customer-facing scientific roles, including technical support, field application scientist, and technical sales. She holds a Ph.D. in Pharmacology from the University of Illinois, Chicago.

12:15 - 13:15 ET ROUNDTABLE 3

Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery



Huseyin Mehmet

Executive Director
University of Massachusetts Medical School

ABOUT THE SPEAKER

Huseyin Mehmet is a drug hunter and research scientist with >35 years' experience in basic and clinical academic research and in pharmaceutical / biotechnology drug discovery. He received his PhD from the Medical Research Council in the UK and went on to work at University College London, the Imperial Cancer Research Fund (now Cancer Research UK), Cold Spring Harbor Lab, USA and then took a faculty position at Imperial College School of Medicine. There his work focused on cerebral hypoxic ischemic injury in neonates and he was part of the team that developed mild hypothermia for the treatment of birth asphyxia. In 2006 Huseyin left the UK to join Merck and Co, in the USA. He worked in biomarker discovery, target identification and several drug discovery programs up to clinical candidate selection. For the next few years, he took on roles with increasing responsibility in several biotech companies and also consulted for a number of start-up companies working with prominent VC firms (e.g. Atlas Ventures and Versant Ventures). Since 2021, Huseyin has led the New Ventures team in the BRIDGE Innovation and Business Development office at UMass Chan Medical School, where he is responsible for the scientific partnering of intellectual property arising from faculty discoveries.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

The Role of Venture Partnerships in Drug Discovery

- Complimentary skills/goals shared by company and the financial partner
- Clear and consistent communication with adapted messaging
- Aligning research goals with milestones that match planned exit and future funding needs



Richard Heidebrecht

Vice President of Research and Development
Glycologix

ABOUT THE SPEAKER

Rich Heidebrecht is currently the Vice President of Research and Development at Glycologix, a clinical-stage biomaterials company. He started his career at Pfizer and Merck before making a transition to Biotech via The Broad Institute. Rich has gained expertise in medicinal, process and analytical chemistry and has worked on diverse therapeutic modalities such as small molecules, cell therapies and polymers including oligonucleotides. Over the course of his career, Rich has contributed to 36 patents/patent applications, 17 papers, five clinical programs and one marketed drug. Doctor Heidebrecht completed his undergraduate work at Worcester Polytechnic Institute and his graduate work at Indiana University with David R. Williams. His postdoc with Stephen Martin at the University of Texas at Austin rounded out two natural product synthesis projects.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
See Page 6

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION

Integrated Drug Discovery

Overcoming the high attrition rates of the development process, particularly in drug discovery and optimization remains a significant hurdle and a top priority in the pharma and biotech sector. Here we will explore effective strategies to break down discipline segmentation and foster an improved integrated approach to drug discovery.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

From Hit to Lead: Accelerating Drug Discovery Through Cutting-Edge Chemistry and Innovative Screening Strategies

- Utilizing 3D cell culture models for more physiologically relevant assays
- Leveraging microfluidic platforms for precise sample handling
- Artificial intelligence (AI) and machine learning to select the most promising compounds from a library in an iterative process
- Target-based and phenotypic screening integration
- Organ-on-a-chip platforms



Shankar Venkatraman
Executive Director
IFM Therapeutics

ABOUT THE SPEAKER
See Page 9

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

The Data Integration Crisis in Drug Discovery: Why Scientists Spend 60% of Their Time on Data Wrangling Instead of Breakthrough Science



Samantha Jeschonek, Ph.D.
Sr. Product Manager Data Analytics
Revvity Signals

revvity
signals

ABOUT THE SPEAKER
Speaker TBC

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

Rewriting the Rules of Therapeutics: The Expanding Frontier of RNA Drug Discovery



Jennifer Petter
Founder and Chief Scientific Officer
Arrakis Therapeutics

ABOUT THE SPEAKER


Dr. Jennifer Petter is the Founder and Chief Scientific Officer of Arrakis Therapeutics. Previously she was Vice President of Chemistry at Celgene, Vice President of Drug Discovery at Avila Therapeutics, Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen, Section Head in Oncology Chemistry at Sandoz/Novartis, and Assistant Professor of Chemistry at the University of Pittsburgh. Dr. Petter graduated from Dartmouth College with an AB in chemistry, earned her PhD in organic chemistry at Duke University with Ned Porter, and was a post-doctoral fellow in Ron Breslow's group at Columbia University. She has ushered more than a dozen compounds into the clinic for the treatment of cancer, cardiovascular disease, autoimmune disorders, and sepsis.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION
See Page 6

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION





Pharma FEATURES

**Find your new partner,
explore our digital storefronts**

www.pharmafeatures.com



Contact us to discuss how we can help generate
growth for your business

Dex Marco Guibelondo

*Marketing Content Writer, Proventa International
Editor-in-Chief, PharmaFEATURES*



dex@proventainternational.com

2025 Strategy Meeting Calendar

MAY



Boston/Cambridge MA - US East Coast

MAY  **CHEMISTRY MANUFACTURING CONTROL**
7 **CMC Strategy Meeting 2025**
WED  Le Meridien Boston Cambridge

MAY  **MEDICINAL CHEMISTRY**
8 **Medicinal Chemistry Strategy Meeting 2025**
THUR  Le Meridien Boston Cambridge

MAY  **VENTURE CAPITAL PRIVATE EQUITY**
7-8 **Venture Capital & Private Equity**
WED&THUR  Le Meridien Boston Cambridge

Princeton/New Jersey - US East Coast


MAY  **MEDICINAL CHEMISTRY**
14 **Medicinal Chemistry Strategy Meeting 2025**
WED  Hyatt Regency Princeton



MAY  **CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN**
15 **Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025**
THUR  Hyatt Regency Princeton



MAY  **VENTURE CAPITAL PRIVATE EQUITY**
14&15 **Venture Capital & Private Equity**
WED&THUR  Hyatt Regency Princeton

OCTOBER

London/UK - Europe



OCT  **CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN**
9 **Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025**
THUR  Crowne Plaza, London Docklands

OCT  **BIOINFORMATICS & DRUG DISCOVERY BIOLOGY**
15 **Bioinformatics & Drug Discovery Biology Strategy Meeting 2025**
WED  Crowne Plaza, London Docklands

OCT  **MEDICINAL CHEMISTRY**
16 **Medicinal Chemistry Strategy Meeting 2025**
THURS  Crowne Plaza, London Docklands

NOVEMBER

San Diego - US West Coast

NOV  **MEDICINAL CHEMISTRY**
12 **Medicinal Chemistry Strategy Meeting 2025**
WED  Hard Rock Hotel San Diego

NOV  **CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN**
13 **Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025**
THUR  Hard Rock Hotel San Diego

Boston/Cambridge MA - US East Coast

NOV  **CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN**
18 **Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025**
TUE  Le Meridien Boston Cambridge

NOV  **BIOINFORMATICS & DRUG DISCOVERY BIOLOGY**
19 **Bioinformatics Strategy Meeting 2025**
WED  Le Meridien Boston Cambridge

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2025

📅 Thursday, 8th May 2025

📍 Le Méridien Boston Cambridge



Hotel & Venue

Le MERIDIEN

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand's European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

[Hotel Details >](#)

[Map & Directions >](#)



STRATEGY
DINNER &
INNOVATION
SPOTLIGHT
SESSION
2025

MAY **21-22**

ESKO BRAND SUMMIT

INNOVATION SPOTLIGHT 2025

📍 Brussels, Belgium

JUNE **24**

REVVITY SIGNALS

STRATEGY DINNER

📍 STK San Francisco, 1 Market St Suite M3, San Francisco,



Learn more about our
Strategy Meetings

www.proventainternational.com ➔